Pallas Capital Advisors LLC Buys Shares of 2,052 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Pallas Capital Advisors LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,052 shares of the biopharmaceutical company’s stock, valued at approximately $486,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ALNY. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Alnylam Pharmaceuticals by 99.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,080 shares of the biopharmaceutical company’s stock worth $8,629,000 after purchasing an additional 22,473 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 3.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 10,805 shares of the biopharmaceutical company’s stock worth $2,068,000 after acquiring an additional 400 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $26,250,000. Greenleaf Trust increased its holdings in shares of Alnylam Pharmaceuticals by 16.0% during the 4th quarter. Greenleaf Trust now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 405 shares during the last quarter. Finally, abrdn plc grew its holdings in shares of Alnylam Pharmaceuticals by 910.7% during the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock worth $44,544,000 after purchasing an additional 209,691 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $19,829,070. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,848 shares of company stock worth $24,683,444. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $1.11 during trading hours on Wednesday, reaching $279.65. The company had a trading volume of 151,528 shares, compared to its average volume of 883,655. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $285.00. The business has a fifty day simple moving average of $237.13 and a 200-day simple moving average of $181.78. The company has a market cap of $35.37 billion, a price-to-earnings ratio of -104.76 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% compared to the same quarter last year. During the same quarter last year, the business posted ($2.21) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on ALNY. TD Cowen increased their target price on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Cantor Fitzgerald increased their target price on Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Seven research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $277.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.